Company news
Halozyme Therapeutics, Inc. (NASDAQ:HALO) news
Every Halozyme Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Halozyme Appoints Dannielle Appelhans to its Board of Directors
August 18, 2026
Halozyme to Report Second Quarter 2026 Financial and Operating Results
July 23, 2026
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA...
July 21, 2026
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA...
July 20, 2026
Halozyme Appoints David Ramsay as President Drug Delivery
June 30, 2026
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug...
June 15, 2026
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
May 11, 2026
Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncolog...
May 7, 2026
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
May 6, 2026
Halozyme to Report First Quarter 2026 Financial and Operating Results
April 30, 2026
Halozyme Appoints Darren Snellgrove as Chief Financial Officer
April 30, 2026
Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series ("ETF Series") and Exchange Traded Fun...
April 14, 2026
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
April 7, 2026
Halozyme Appoints David Ramsay as Interim Chief Financial Officer
March 12, 2026
Breakout Ventures Launches Fund III with $114M to Continue Building the Future Powered by Science
March 10, 2026
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma
March 6, 2026
Russell Investments Expands Canadian ETF Lineup With Five New Offerings
February 18, 2026
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
February 17, 2026
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results
February 10, 2026
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
January 28, 2026
Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update
January 20, 2026
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®
January 8, 2026
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Ob...
January 5, 2026
Huonslab Announces Submission of Biologics License Application for Recombinant Human Hyaluronidase ‘HYDIZYME™’
December 22, 2025
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-m...
December 18, 2025
Bench International Announces Appointment of Jim Lang to the Board of Directors of Halozyme Therapeutics
December 17, 2025
Jim Lang Elected to Halozyme's Board of Directors
December 8, 2025
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
December 4, 2025
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference
November 25, 2025
Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery
November 18, 2025
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
November 17, 2025
FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma
November 7, 2025
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million o...
November 6, 2025
Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Converti...
November 5, 2025
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS
November 3, 2025
Halozyme to Report Third Quarter 2025 Financial and Operating Results
October 21, 2025
Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s
October 1, 2025
Halozyme to Participate at Upcoming Investor Conferences
August 28, 2025
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS
August 5, 2025
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
July 23, 2025
Halozyme to Report Second Quarter 2025 Financial and Operating Results
July 22, 2025
Halozyme Therapeutics Added to Russell 1000® Index
June 30, 2025
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammator...
June 20, 2025
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENH...
May 28, 2025
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
May 6, 2025
Halozyme to Participate in the BofA Securities 2025 Healthcare Conference
May 5, 2025
Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chroni...
April 28, 2025
Halozyme to Report First Quarter 2025 Financial and Operating Results
April 28, 2025
Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation
April 24, 2025
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for General...
April 10, 2025